SHH and neoplasm: For stage I NSCLC, patients with tumor relapse within 12 months after surgery had a higher percentage of Shh+ cells in their tumors than those without tumor relapse within 12 months of surgery [median: 0.19% (IQR 0.14-0.36) versus 0.05% (IQR 0.02-0.09), respectively, p=0.01; analysis based on 22 stage I NSCLC with follow-up > 12 months after surgery] (Figure 6F).